VivoSeq
Other

KRAS G12D

3

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

KRAS G12D is an early-stage landscape with 3 programs across 3 companies. The most active players are Genfleet Therapeutics (Shanghai) Inc., Avyxa, Quanta Therapeutics. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Genfleet Therapeutics (Shanghai) Inc.

1 program

Phase 3A

Avyxa

1 program

Phase 3Q

Quanta Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

ARV-806

Arvinas Inc.

Phase 1
No programs
Phase 2
No programs
Phase 32

GFH375

Genfleet Therapeutics (Shanghai) Inc.

Docetaxel

Avyxa

Approved
No programs

Analysis

Trial Status

4

clinical trials

Active, not recruiting2 · 50%
Recruiting1 · 25%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

QTX3046 in Patients With KRAS G12D Mutations
Active, not recruiting·QQuanta Therapeutics·Phase 1·NCT06428500·240 enrolled
QTX3034 in Patients With KRAS G12D Mutation
Recruiting·QQuanta Therapeutics·Phase 1·NCT06227377·250 enrolled
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Active, not recruiting·AArvinas Inc.·Preclinical·NCT07023731·159 enrolled
A Phase III, Randomized, Open-Label, Multicenter Study to Evaluate GFH375 Versus Docetaxel in Participants With Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer With KRAS G12D Mutation Failed Prior Standard Therapy
Not yet recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 3·NCT07668752·300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)